The global Inactivated Vaccine for Swine Mycoplasma Pneumonia market size was estimated at USD 342 million in 2024 and is projected to reach USD 650.23 million by 2032, exhibiting a CAGR of 7.40% during the forecast period.
North America Inactivated Vaccine for Swine Mycoplasma Pneumonia market size was estimated at USD 100.78 million in 2024, at a CAGR of 6.34% during the forecast period of 2025 through 2032.
Report Overview
Inactivated vaccines for Swine Mycoplasma pneumonia are also available. They are made by using inactivated or killed strains of the bacteria to stimulate an immune response in pigs without causing disease.
This report provides a deep insight into the global Inactivated Vaccine for Swine Mycoplasma Pneumonia market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Inactivated Vaccine for Swine Mycoplasma Pneumonia market in any manner.
Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Zoetis
- Boehringer Ingelheim
- Jinhe Biotechnology
- Merck
- HIPRA
- Ceva Santé Animale
- Harbin Pharmaceutical Group
- Pulike Biotech
- Qilu Animal Health Products
- Wuhan Keqian Biology
Market Segmentation (by Type)
- Single Vaccine
- Dual Vaccine
Market Segmentation (by Application)
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Inactivated Vaccine for Swine Mycoplasma Pneumonia Market
- Overview of the regional outlook of the Inactivated Vaccine for Swine Mycoplasma Pneumonia Market:
FAQs: Inactivated Vaccine for Swine Mycoplasma Pneumonia Market (2024-2032)
1. What is the projected market size of the Inactivated Vaccine for Swine Mycoplasma Pneumonia by 2032?
-
The global market for Inactivated Vaccines for Swine Mycoplasma Pneumonia is projected to reach USD 650.23 million by 2032, growing at a CAGR of 7.40% from USD 342 million in 2024.
2. What factors are driving the growth of the Inactivated Swine Mycoplasma Pneumonia Vaccine market?
Key factors contributing to market growth include:
-
Rising prevalence of Mycoplasma hyopneumoniae infections in swine.
-
Increased demand for effective disease prevention in commercial pig farming.
-
Government initiatives promoting livestock health and biosecurity.
-
Advancements in vaccine formulations and production technologies.
3. What are the key challenges in the Inactivated Swine Mycoplasma Pneumonia Vaccine market?
Challenges include:
-
High R&D costs associated with vaccine development.
-
Strict regulatory approval processes for veterinary vaccines.
-
Limited awareness among small-scale pig farmers in certain regions.
4. Which regions are expected to dominate the market?
-
North America, Europe, and Asia-Pacific are expected to be the key revenue-generating regions. Asia-Pacific, particularly China and Southeast Asia, is anticipated to witness the fastest growth due to the high swine population and increasing adoption of vaccines.
5. Who are the major players in the Inactivated Vaccine for Swine Mycoplasma Pneumonia market?
Leading manufacturers include:
-
Zoetis Inc.
-
Boehringer Ingelheim
-
Ceva Santé Animale
-
Merck & Co., Inc.
-
Hipra
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porters five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
Customization of the Report
- In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
- Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
- Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Inactivated Vaccine for Swine Mycoplasma Pneumonia Market and its likely evolution in the short to mid-term, and long term.
- Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
- Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
- Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
- Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
- Chapter 9 shares the main producing countries of Inactivated Vaccine for Swine Mycoplasma Pneumonia, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
- Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
- Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
- Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
- Chapter 13 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Inactivated Vaccine for Swine Mycoplasma Pneumonia
1.2 Key Market Segments
1.2.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Segment by Type
1.2.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Overview
2.1 Global Market Overview
2.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Competitive Landscape
3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Manufacturers (2019-2025)
3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share by Manufacturers (2019-2025)
3.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Sites, Area Served, Product Type
3.6 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Competitive Situation and Trends
3.6.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Concentration Rate
3.6.2 Global 5 and 10 Largest Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Chain Analysis
4.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Inactivated Vaccine for Swine Mycoplasma Pneumonia Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Type (2019-2025)
6.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Market Share by Type (2019-2025)
6.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2019-2025)
7 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Sales by Application (2019-2025)
7.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) by Application (2019-2025)
7.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Growth Rate by Application (2019-2025)
8 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Consumption by Region
8.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region
8.2 North America
8.2.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Production by Region
9.1 Global Production of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Region (2019-2025)
9.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share by Region (2019-2025)
9.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Production
9.4.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Growth Rate (2019-2025)
9.4.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Production
9.5.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Growth Rate (2019-2025)
9.5.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (2019-2025)
9.6.1 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Growth Rate (2019-2025)
9.6.2 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (2019-2025)
9.7.1 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Growth Rate (2019-2025)
9.7.2 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Zoetis
10.1.1 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
10.1.2 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
10.1.3 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
10.1.4 Zoetis Business Overview
10.1.5 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
10.1.6 Zoetis Recent Developments
10.2 Boehringer Ingelheim
10.2.1 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
10.2.2 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
10.2.3 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
10.2.4 Boehringer Ingelheim Business Overview
10.2.5 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
10.2.6 Boehringer Ingelheim Recent Developments
10.3 Jinhe Biotechnology
10.3.1 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
10.3.2 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
10.3.3 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
10.3.4 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
10.3.5 Jinhe Biotechnology Business Overview
10.3.6 Jinhe Biotechnology Recent Developments
10.4 Merck
10.4.1 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
10.4.2 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
10.4.3 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
10.4.4 Merck Business Overview
10.4.5 Merck Recent Developments
10.5 HIPRA
10.5.1 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
10.5.2 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
10.5.3 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
10.5.4 HIPRA Business Overview
10.5.5 HIPRA Recent Developments
10.6 Ceva Sant� Animale
10.6.1 Ceva Sant� Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
10.6.2 Ceva Sant� Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
10.6.3 Ceva Sant� Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
10.6.4 Ceva Sant� Animale Business Overview
10.6.5 Ceva Sant� Animale Recent Developments
10.7 Harbin Pharmaceutical Group
10.7.1 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
10.7.2 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
10.7.3 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
10.7.4 Harbin Pharmaceutical Group Business Overview
10.7.5 Harbin Pharmaceutical Group Recent Developments
10.8 Pulike Biotech
10.8.1 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
10.8.2 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
10.8.3 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
10.8.4 Pulike Biotech Business Overview
10.8.5 Pulike Biotech Recent Developments
10.9 Qilu Animal Health Products
10.9.1 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
10.9.2 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
10.9.3 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
10.9.4 Qilu Animal Health Products Business Overview
10.9.5 Qilu Animal Health Products Recent Developments
10.10 Wuhan Keqian Biology
10.10.1 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
10.10.2 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
10.10.3 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Market Performance
10.10.4 Wuhan Keqian Biology Business Overview
10.10.5 Wuhan Keqian Biology Recent Developments
11 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast by Region
11.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast
11.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country
11.2.3 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Region
11.2.4 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2025-2032)
12.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2025-2032)
12.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Forecast by Application (2025-2032)
12.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT) Forecast by Application
12.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Comparison by Region (M USD)
Table 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine for Swine Mycoplasma Pneumonia as of 2022)
Table 10. Global Market Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Sites and Area Served
Table 12. Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Type
Table 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
Table 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Type (K MT)
Table 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Type (M USD)
Table 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT) by Type (2019-2025)
Table 25. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Type (2019-2025)
Table 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) by Type (2019-2025)
Table 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Share by Type (2019-2025)
Table 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price (USD/MT) by Type (2019-2025)
Table 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT) by Application
Table 30. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Application
Table 31. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Application (2019-2025) & (K MT)
Table 32. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Application (2019-2025)
Table 33. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Application (2019-2025) & (M USD)
Table 34. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application (2019-2025)
Table 35. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Growth Rate by Application (2019-2025)
Table 36. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region (2019-2025) & (K MT)
Table 37. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region (2019-2025)
Table 38. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country (2019-2025) & (K MT)
Table 39. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region (2019-2025) & (K MT)
Table 41. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales by Region (2019-2025) & (K MT)
Table 43. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K MT) by Region (2019-2025)
Table 44. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share by Region (2019-2025)
Table 46. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 52. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 53. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. Zoetis Business Overview
Table 55. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
Table 56. Zoetis Recent Developments
Table 57. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 58. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 59. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. Boehringer Ingelheim Business Overview
Table 61. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
Table 62. Boehringer Ingelheim Recent Developments
Table 63. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 64. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 65. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia SWOT Analysis
Table 67. Jinhe Biotechnology Business Overview
Table 68. Jinhe Biotechnology Recent Developments
Table 69. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 70. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 71. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. Merck Business Overview
Table 73. Merck Recent Developments
Table 74. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 75. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 76. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. HIPRA Business Overview
Table 78. HIPRA Recent Developments
Table 79. Ceva Sant� Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 80. Ceva Sant� Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 81. Ceva Sant� Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. Ceva Sant� Animale Business Overview
Table 83. Ceva Sant� Animale Recent Developments
Table 84. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 85. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 86. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. Harbin Pharmaceutical Group Business Overview
Table 88. Harbin Pharmaceutical Group Recent Developments
Table 89. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 90. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 91. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 92. Pulike Biotech Business Overview
Table 93. Pulike Biotech Recent Developments
Table 94. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 95. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 96. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 97. Qilu Animal Health Products Business Overview
Table 98. Qilu Animal Health Products Recent Developments
Table 99. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Basic Information
Table 100. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Overview
Table 101. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 102. Wuhan Keqian Biology Business Overview
Table 103. Wuhan Keqian Biology Recent Developments
Table 104. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Region (2025-2032) & (K MT)
Table 105. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Region (2025-2032) & (M USD)
Table 106. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Country (2025-2032) & (K MT)
Table 107. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2032) & (M USD)
Table 108. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Country (2025-2032) & (K MT)
Table 109. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2032) & (M USD)
Table 110. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Region (2025-2032) & (K MT)
Table 111. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Region (2025-2032) & (M USD)
Table 112. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Country (2025-2032) & (K MT)
Table 113. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2032) & (M USD)
Table 114. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Consumption Forecast by Country (2025-2032) & (Units)
Table 115. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Country (2025-2032) & (M USD)
Table 116. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Type (2025-2032) & (K MT)
Table 117. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Type (2025-2032) & (M USD)
Table 118. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price Forecast by Type (2025-2032) & (USD/MT)
Table 119. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT) Forecast by Application (2025-2032)
Table 120. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD), 2019-2032
Figure 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size (M USD) (2019-2032)
Figure 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size by Country (M USD)
Figure 11. Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Share by Manufacturers in 2023
Figure 12. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Share by Manufacturers in 2023
Figure 13. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Type
Figure 18. Sales Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2019-2025)
Figure 19. Sales Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type in 2023
Figure 20. Market Size Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type (2019-2025)
Figure 21. Market Size Market Share of Inactivated Vaccine for Swine Mycoplasma Pneumonia by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application
Figure 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Application (2019-2025)
Figure 25. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Application in 2023
Figure 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application (2019-2025)
Figure 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Application in 2023
Figure 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Growth Rate by Application (2019-2025)
Figure 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region (2019-2025)
Figure 30. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Country in 2023
Figure 32. U.S. Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Country in 2023
Figure 37. Germany Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region in 2023
Figure 44. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (K MT)
Figure 50. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Country in 2023
Figure 51. Brazil Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Production Market Share by Region (2019-2025)
Figure 62. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K MT) Growth Rate (2019-2025)
Figure 65. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share Forecast by Type (2025-2032)
Figure 70. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Forecast by Application (2025-2032)
Figure 71. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share Forecast by Application (2025-2032)
